Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber, Alan
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [electronic resource] - Lancet (London, England) Feb 2009 - 473-81 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1474-547X
10.1016/S0140-6736(08)61246-5 doi
Blood Glucose--drug effects
Blood Pressure--drug effects
Diabetes Mellitus, Type 2--drug therapy
Double-Blind Method
Female
Glucagon-Like Peptide 1--adverse effects
Glycated Hemoglobin--drug effects
Humans
Hypoglycemic Agents--adverse effects
Liraglutide
Male
Middle Aged
Sulfonylurea Compounds--adverse effects
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [electronic resource] - Lancet (London, England) Feb 2009 - 473-81 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1474-547X
10.1016/S0140-6736(08)61246-5 doi
Blood Glucose--drug effects
Blood Pressure--drug effects
Diabetes Mellitus, Type 2--drug therapy
Double-Blind Method
Female
Glucagon-Like Peptide 1--adverse effects
Glycated Hemoglobin--drug effects
Humans
Hypoglycemic Agents--adverse effects
Liraglutide
Male
Middle Aged
Sulfonylurea Compounds--adverse effects